Display options
Cite
Parker KJ, Oztan O, Libove RA, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019;11(491)doi: 10.1126/scitranslmed.aau7356.
Parker, K. J., Oztan, O., Libove, R. A., Mohsin, N., Karhson, D. S., Sumiyoshi, R. D., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., Carson, D. S., Fung, L. K., Garner, J. P., & Hardan, A. Y. (2019). A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science translational medicine, 11(491), . https://doi.org/10.1126/scitranslmed.aau7356
Parker, Karen J, et al. "A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism." Science translational medicine vol. 11,491 (2019). doi: https://doi.org/10.1126/scitranslmed.aau7356
Parker KJ, Oztan O, Libove RA, Mohsin N, Karhson DS, Sumiyoshi RD, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Fung LK, Garner JP, Hardan AY. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019 May 08;11(491). doi: 10.1126/scitranslmed.aau7356. Epub 2019 May 01. PMID: 31043522; PMCID: PMC6716148.
Copy Download .nbib Format: NLM
Share it on

Sci Transl Med. 2019 May 08;11(491). doi: 10.1126/scitranslmed.aau7356. Epub 2019 May 01.

A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism.

Science translational medicine

Karen J Parker, Ozge Oztan, Robin A Libove, Noreen Mohsin, Debra S Karhson, Raena D Sumiyoshi, Jacqueline E Summers, Kyle E Hinman, Kara S Motonaga, Jennifer M Phillips, Dean S Carson, Lawrence K Fung, Joseph P Garner, Antonio Y Hardan

Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA. [email protected].
  2. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
  3. Department of Pediatrics, Stanford University, Stanford, CA 94305, USA.
  4. Department of Comparative Medicine, Stanford University, Stanford, CA 94305, USA.

PMID: 31043522 PMCID: PMC6716148 DOI: 10.1126/scitranslmed.aau7356

Abstract

The social impairments of autism spectrum disorder (ASD) have a major impact on quality of life, yet there are no medications that effectively treat these core social behavior deficits. Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD. Using a double-blind, randomized, placebo-controlled, parallel study design, we tested the efficacy and tolerability of a 4-week intranasal AVP daily treatment in 30 children with ASD. AVP-treated participants aged 6 to 9.5 years received the maximum daily target dose of 24 International Units (IU); participants aged 9.6 to 12.9 years received the maximum daily target dose of 32 IU. Intranasal AVP treatment compared to placebo enhanced social abilities as assessed by change from baseline in this phase 2 trial's primary outcome measure, the Social Responsiveness Scale, 2nd Edition total score (SRS-2

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

References

  1. Pediatr Res. 2011 May;69(5 Pt 2):55R-62R - PubMed
  2. J Neuroendocrinol. 2013 Jul;25(7):668-73 - PubMed
  3. Ann Neurol. 2018 Oct;84(4):611-615 - PubMed
  4. J Med Chem. 2015 Mar 12;58(5):2275-89 - PubMed
  5. PLoS One. 2016 Oct 27;11(10):e0165401 - PubMed
  6. Psychoneuroendocrinology. 2004 Jan;29(1):35-48 - PubMed
  7. Physiol Behav. 2015 Nov 1;151:485-93 - PubMed
  8. Eur J Clin Invest. 1984 Dec;14(6):435-9 - PubMed
  9. Psychoneuroendocrinology. 2014 Jul;45:128-41 - PubMed
  10. Am J Psychiatry. 1986 Jan;143(1):35-9 - PubMed
  11. J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
  12. BMC Med. 2009 Oct 22;7:62 - PubMed
  13. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19144-9 - PubMed
  14. Psychoneuroendocrinology. 2011 Feb;36(2):294-7 - PubMed
  15. Behav Neurosci. 2010 Feb;124(1):159-163 - PubMed
  16. Sci Transl Med. 2019 May 8;11(491): - PubMed
  17. Trends Neurosci. 2012 Nov;35(11):649-59 - PubMed
  18. Mol Psychiatry. 2016 Sep;21(9):1225-31 - PubMed
  19. PLoS One. 2014 Jan 21;9(1):e85268 - PubMed
  20. Peptides. 2014 Nov;61:12-6 - PubMed
  21. Eur Child Adolesc Psychiatry. 2018 Dec;27(12):1523-1537 - PubMed
  22. Nature. 1999 Aug 19;400(6746):766-8 - PubMed
  23. Physiol Behav. 1996 Jul;60(1):25-9 - PubMed
  24. J Autism Dev Disord. 2003 Aug;33(4):427-33 - PubMed
  25. Psychoneuroendocrinology. 1982;7(2-3):185-93 - PubMed
  26. BMC Genet. 2012 Dec 12;13:106 - PubMed
  27. Neurosci Biobehav Rev. 2017 May;76(Pt A):87-98 - PubMed
  28. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124 - PubMed
  29. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2051-6 - PubMed
  30. J Autism Dev Disord. 2016 Jul;46(7):2464-79 - PubMed
  31. Curr Drug Saf. 2007 Sep;2(3):232-8 - PubMed
  32. Neuropsychopharmacology. 2004 Mar;29(3):483-93 - PubMed
  33. Autism. 2014 Jan;18(1):31-44 - PubMed
  34. Psychiatry Res. 2009 Aug 15;168(3):242-9 - PubMed
  35. eNeuro. 2016 Apr 06;3(2): - PubMed
  36. Mol Psychiatry. 2008 Aug;13(8):786-99, 741 - PubMed
  37. Neuroscience. 1998 Aug;85(4):1209-22 - PubMed
  38. J Neurosci. 1997 Jun 1;17(11):4331-40 - PubMed
  39. Horm Behav. 2012 Mar;61(3):283-92 - PubMed
  40. Mol Psychiatry. 2016 Jan;21(1):29-38 - PubMed
  41. Nat Neurosci. 2002 Jun;5(6):514-6 - PubMed
  42. PLoS One. 2015 Jul 22;10(7):e0132224 - PubMed
  43. J Autism Dev Disord. 2007 May;37(5):855-66 - PubMed
  44. Biol Psychiatry. 2005 Mar 15;57(6):655-60 - PubMed
  45. J Autism Dev Disord. 1994 Oct;24(5):659-85 - PubMed
  46. Span J Psychol. 2007 May;10(1):178-88 - PubMed
  47. Front Neurosci. 2015 Sep 24;9:335 - PubMed
  48. Mol Biol Cell. 2004 Dec;15(12):5693-9 - PubMed
  49. J Child Adolesc Psychopharmacol. 2017 Jun;27(5):403-412 - PubMed
  50. Arch Gen Psychiatry. 2003 May;60(5):524-30 - PubMed
  51. J Child Adolesc Psychiatr Ment Health Nurs. 1991 Oct-Dec;4(4):127-31 - PubMed
  52. MMWR Surveill Summ. 2016 Apr 01;65(3):1-23 - PubMed
  53. Nature. 1993 Oct 7;365(6446):545-8 - PubMed
  54. Nat Biotechnol. 2010 Aug;28(8):772-4 - PubMed
  55. Neuropsychopharmacology. 2017 Aug;42(9):1924 - PubMed
  56. Annu Rev Pharmacol Toxicol. 2001;41:175-202 - PubMed
  57. Horm Behav. 2001 Jun;39(4):285-94 - PubMed
  58. Clin Psychol Rev. 2009 Apr;29(3):216-29 - PubMed
  59. Sci Transl Med. 2018 May 2;10(439): - PubMed
  60. Biol Psychiatry. 2010 Jun 15;67(12):1220-2 - PubMed
  61. Res Dev Disabil. 2012 Jul-Aug;33(4):1136-46 - PubMed

Substances

MeSH terms

Publication Types

Grant support